Clinical trials: Breast Cancer (Early Breast Cancer)
Chemotherapeutic Toxicity, Cardiotoxicity
Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical…
- Conditions
- Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure, Breast Cancer
- Trial name
- NCT05892146
- Testing
- Prevention therapy, Rescue therapy
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Cheng-Kung University Hospital
Breast Cancer Detection
Early Detection of Breast Cancer Among Syrian Women
The goal of this observational study is to evaluate breast cancer awareness, screening practices, and barriers to early detection among women in the middle region of Syria. The main questions it aims to answer are: 1.
- Trial name
- NCT07056686
- Testing
- Mammogram
- Where
- Syria
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Al-Hawash Private University
Breast Neoplasms
MRI and Early Decision-making in Chemotherapy for Breast Cancer
Firstly, the investigators aim to show that breast tumour blood flow, measured as part of a standard MRI examination, decreases at the earliest stage of neoadjuvant chemotherapy in those patients who go on to respond to…
- Trial name
- CHERNAC (NCT02449824)
- Testing
- magnetic resonance imaging
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Leeds
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Some cancer treatments, such as anthracycline chemotherapy and HER2-targeted therapy, can damage the heart (cardiotoxicity). If heart damage is detected early, heart-protective treatment can be started and cancer treatment can…
- Conditions
- Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer, Cardiotoxicity
- Trial name
- SAFE-HEART (NCT07916337)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Skane
Breast Cancer
Patient-centered Communication About Healthy Weight in Early Breast Cancer
Comorbidities in breast cancer survival account for 49% of overall survival difference between black and white women. Many obesity-related comorbidities disproportionately affect black women, therefore pointing to a need to…
- Trial name
- NCT04504201
- Testing
- Focus Group
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy.
- Trial name
- RAGE (NCT05256745)
- Testing
- TTP488, ddAC/ddT, TC
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Georgetown University
Breast Cancer, Menopausal Symptoms
Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
RATIONALE: Hormone replacement therapy is effective for relieving symptoms of menopause. It is not yet known if hormone replacement therapy increases the risk of breast cancer recurrence in women previously treated for early…
- Trial name
- NCT00003771
- Testing
- therapeutic estradiol, norethindrone acetate
- Where
- 6 sites in Finland, Norway and 3 more
- Volunteers
- 1,300 people
- Sponsor
- Regional Oncologic Center
Early Stage Breast Cancer
A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates. Improvements in outcomes, however, are compromised by the considerable toxicities associated with chemotherapy, the most notable…
- Trial name
- REaCT-G2 (NCT02816164)
- Testing
- Neupogen
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer
After breast cancer patients complete the acute phase of their treatment (i.e. surgery, chemotherapy and/or radiation therapy), they are routinely followed in clinic every 3-6 months for several years.
- Trial name
- NCT05365230
- Testing
- On-demand personalized follow-up care, Guideline-based follow-up care (standard of care)
- Where
- Canada
- Volunteers
- 261 people
- Sponsor
- Ottawa Hospital Research Institute
TNBC, TNBC - Triple-Negative Breast Cancer
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer.
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07017673
- Testing
- Ivonescimab, Carboplatin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Cedars-Sinai Medical Center
HER2-positive Breast Cancer, Early-stage Breast Cancer
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer.
- Trial name
- DEFINITIVE (NCT06446882)
- Testing
- Personalized treatment according to molecular diagnosis with HER2DX, Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
- Where
- 29 sites in Austria, France and 3 more
- Volunteers
- 304 people
- Sponsor
- Fundacio Clinic Barcelona
Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes
Omission of SLNB in CN0 Early Breast Cancer
The OMSLNB trial adopts a prospective, single-arm, non-inferiority, phase-II, open-label study design. Patients with unilateral invasive breast cancer （tumor ≤3cm） and assessed as cN0 will be eligible for inclusion, enrolled…
- Conditions
- Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node
- Trial name
- NCT05935150
- Testing
- Omit SLNB
- Where
- China
- Volunteers
- 311 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life…
- Trial name
- NCT05926024
- Testing
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
This phase II trial studies how well oxaloacetate works in reducing cognitive complaints in stage 0-IIIA breast cancer survivors. Oxaloacetate is a natural substance found in the body and is available as a nutritional supplement.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04290897
- Testing
- Anhydrous Enol-oxaloacetate, Questionnaire Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment.
- Trial name
- NCT04134780
- Where
- 3 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer
The HIFUB Study (HIFU in Breast Cancer)
High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive…
- Trial name
- HIFUB (NCT05350059)
- Testing
- High Intensity Focused Ultrasound (HIFU) to the Breast Cancer
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Breast Neoplasms
In Vitro Study of the Liquid Biopsy Test System of the Diagnostic Value, in Women With Various Forms of Breast Cancer
The Study Objective is to evaluate the diagnostic efficacy of the liquid biopsy system versus the gold standard mammography (or MRI, or Ultrasound) diagnosis in patients with suspected breast cancer.
- Trial name
- ARNABreast (NCT04890340)
- Testing
- ARNA Breast
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- ARNA Genomics US Inc.
Breast Cancer
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA
CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.
- Trial name
- GALIA (NCT07418125)
- Testing
- Liquid biopsy
- Where
- Slovenia
- Volunteers
- 130 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00949013
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 1,600 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.